VP of Life Sciences Committee, Tech Coast Angels
After receiving a BS in biology from MIT, Jeff earned a MD and PhD in Cancer Biology at Stanford University. His thesis elucidated the mechanism of action of the immunosuppressive drugs cyclosporine A and FK506. Dr. Friedman went on to train in Pediatrics at Boston Children’s Hospital and was a fellow in Pediatric Hematology/ Oncology at the Dana Farber Cancer Institute. From 2003-2012 Dr. Friedman was a Principal Investigator and Assistant Professor at the Scripps Research Institute (La Jolla, CA) studying red cell and bone marrow disorders.
Currently, Dr. Friedman oversees a mixed portfolio of more than 20 private and 20 public companies in the biotechnology and pharmaceutical space, with an emphasis on platform technologies, oncology, neurodegenerative disease and genomics. He is the Managing Partner of Friedman Bioventure Fund 1, a family investment vehicle newly capitalized in 2016. Dr. Friedman served on the board of directors of Cypher Genomics (2012-15) until it was acquired by Human Longevity, Inc in November of 2015. Dr. Friedman currently serves on the board of Celsense, a company developing enabling tools for cellular therapeutics, and Matrisys Bioscience, a micro biome company developing live biologic therapeutics for treatment of dermatologic disorders. He is on the board and is VP of Life Sciences for Tech Coast Angels in San Diego, one of the largest and most active Angel Investment groups in the US. He also is Chair of the Research Committee and a board member of CurePSP, a nationwide foundation funding research and providing education and support to patients with Progressive Supranuclear Palsy (PSP) and to their families and caregivers.
Dr. Friedman is also the managing director of the recently formed PSP Genetics Consortium, an international effort to sequence the genomes of up to 2,500 individuals with PSP, funded by the Tau Consortium and CurePSP. Jeff is married to Dr. Jennifer Friedman, Clinical Professor of Neurosciences and Pediatrics at UCSD who practices as a neurologist, neuro-genetics and movement disorder specialist at Rady Children’s Hospital San Diego.
This panel discussion will focus on some of the strategic funding avenues available and how to improve your funding chances, including the recent REG. A+ IPO.
Five pre-selected companies will each give five-minute pitches to these investors, while receiving on-the-spot critiques. The hot seat is a fast, fun, and interactive format, giving entrepreneurs the opportunity to pitch their technologies in front of world-class leaders and investors. Voted on by audience members using their mobile devices, as well as the investor panel […]